A new, effective, safer agent for type 2 diabetes

File:Gestational diabetes kit.jpg

TAK-875, which will no doubt get a catchier name in the next few months, adds to our ever growing collection of options for type 2 diabetes – like GLP-1  agonists and DPP-IV inhibitors. So is it just going to fall by the wayside or be another useful addition?The Lancet reports on a phase 2, randomised double blind placebo controlled trial, comparing this new agent (working on fatty acid stimulated glucose dependent insulin secretion) to glimepiride. Overall, it improved HbA1c, hypoglycaemia was similar to placebo, and adverse events were reasonable – this could become the next new agent.

The final nail in the coffin for sulfonylureas? We’ll soon see. In the meantime, check this out here.

image | Jessica Merz

source | The Lancet

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s